https://www.selleckchem.com/products/tvb-3664.html
Hepatocellular carcinoma (HCC) is a frequent and increasing cause of cancer-related deaths worldwide. Reversing this trend is complicated by the varied aetiological factors leading to liver cirrhosis resulting in molecular genetic and clinical heterogeneity, combined with frequent presentation at advanced stage. Large-scale genomic studies have identified alterations in key signalling pathways for HCC development and progression, but these findings have not yet directly influenced patient management in the clinical setting. Despite the
Like
Comment
Share
